| Authors: |
Brufsky A; Department of Medicine, Hematology/Oncology, University of Pittsburgh School of Medicine, PA., Tolaney SM; Dana-Farber Cancer Institute, Boston, MA., Gadi VK; University of Illinois Cancer Center, Chicago., Chai X; Analysis Group, Inc., Boston, MA., Yang F; Analysis Group, Inc., Boston, MA., Chen W; Analysis Group, Inc., Boston, MA., Ma W; Analysis Group, Inc., Boston, MA., Zhou ZY; Analysis Group, Inc., Boston, MA., Ganapathy V; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Patel A; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Sopher G; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Alexander E; Novartis Ireland Ltd., Dublin, Ireland., Bollu V; Novartis Pharmaceuticals Corporation, East Hanover, NJ., Garrison LP Jr; The CHOICE Institute, Department of Pharmacy, University of Washington, Seattle., Sparano JA; Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY. |
